Windlas Biotech Restricted, a number one Indian pharmaceutical CDMO, introduced as we speak that its new injectable manufacturing facility has acquired Good Manufacturing Practices (GMP) certification from Uttarakhand’s Meals Security & Medicine Administration Authority. The certification, following a December 2024 inspection, confirms the ability’s compliance with WHO TRS Pointers.
The shares of Windlas Biotech Restricted have been buying and selling at ₹1,007.10 down by ₹8.95 or 0.88 per cent on the NSE as we speak at 2.20 pm.
The newly licensed facility, outfitted with automated techniques and high quality management mechanisms, represents the corporate’s fifth GMP-compliant manufacturing plant. Managing Director Hitesh Windlass acknowledged that the certification would allow the corporate to develop its product portfolio within the CDMO house and meet rising demand for injectable pharmaceutical merchandise in home and world markets.
- Additionally learn: Liquidity administration could take precedence over charge cuts in February MPC
Windlas Biotech, ranked amongst India’s prime 5 pharmaceutical formulations CDMO gamers, has over 20 years of expertise manufacturing strong and liquid pharmaceutical dosage types. The corporate specialises in excessive efficiency and managed substances manufacturing, whereas additionally advertising and marketing branded commerce generics and institutional merchandise throughout India.
The GMP certification marks a big enlargement of Windlas Biotech’s manufacturing capabilities, significantly in sterile injectable formulations. The corporate’s new facility options eco-friendly processes and superior infrastructure designed for environment friendly manufacturing of sterile injectables, positioning it to serve a wider vary of therapeutic areas.
